Theriva Biologics Inc
SYN
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.16M
Close$
$1.57
54.2% upside
Current Fair Value
54.2% upsideUndervalued by 54.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.16 Million |
|---|---|
| Enterprise Value | $3.80 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.08 |
| Beta | 1.39 |
| Outstanding Shares | 41,072,725 |
Return
| Return on Equity | -149.16% |
|---|---|
| Return on Assets | -60.05% |
| Return on Invested Capital | -77.86% |
Valuation & Multiples
| P/E Ratio | -0.54 |
|---|---|
| PEG | 1.03 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.54 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Synthetic Biologics Inc
CEO: Steven Shallcross